levofloxacin

Susceptibility
Levofloxacin-Resistant Invasive Streptococcus pneumoniae in the United States: Evidence for Clonal Spread and the Impact of Conjugate Pneumococcal Vaccine
Mathias W. R. Pletz, Lesley McGee, James Jorgensen, Bernard Beall, Richard R. Facklam, Cynthia G. Whitney, Keith P. Klugman
and the Active Bacterial Core Surveillance Team
Experimental Therapeutics
Novel Murine Model of Pneumococcal Pneumonia: Use of Temperature as a Measure of Disease Severity To Compare the Efficacies of Moxifloxacin and Levofloxacin
Darrin J. Bast, M. Yue, X. Chen, D. Bell, L. Dresser, R. Saskin, L. A. Mandell, D. E. Low, Joyce C. S. de Azavedo
Susceptibility
In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA
Raymond P. Smith, Aldona L. Baltch, William J. Ritz, Andrea N. Carpenter, Tanya A. Halse, Lawrence H. Bopp
Experimental Therapeutics
Effectiveness of Ciprofloxacin, Levofloxacin, or Moxifloxacin for Treatment of Experimental Staphylococcus aureus Keratitis
Joseph J. Dajcs, Brett A. Thibodeaux, Mary E. Marquart, Dalia O. Girgis, Mullika Traidej, Richard J. O'Callaghan
Experimental Therapeutics
Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy
Delphine Croisier, Manuel Etienne, Emilie Bergoin, Pierre-Emmanuel Charles, Catherine Lequeu, Lionel Piroth, Henri Portier, Pascal Chavanet
Pharmacology
Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae
Naomi R. Florea, Pamela R. Tessier, Cuilian Zhang, Charles H. Nightingale, David P. Nicolau
Experimental Therapeutics
In Vitro Pharmacodynamic Activities of ABT-492, a Novel Quinolone, Compared to Those of Levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
Shana M. Gunderson, Robert A. Hayes, John P. Quinn, Larry H. Danziger
Pharmacology
Relevance of Soft-Tissue Penetration by Levofloxacin for Target Site Bacterial Killing in Patients with Sepsis
M. A. Zeitlinger, P. Dehghanyar, B. X. Mayer, B. S. Schenk, U. Neckel, G. Heinz, A. Georgopoulos, M. Müller, C. Joukhadar
Susceptibility
Postantibiotic, Postantibiotic Sub-MIC, and Subinhibitory Effects of PGE-9509924, Ciprofloxacin, and Levofloxacin
Inga Odenholt, Elisabeth Löwdin, Otto Cars
Pharmacology
Levofloxacin Disposition in Cerebrospinal Fluid in Patients with External Ventriculostomy
Federico Pea, Federica Pavan, Ennio Nascimben, Claudio Benetton, Pier Giorgio Scotton, Alberto Vaglia, Mario Furlanut

Pages